Sudeepa Bhattacharyya

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Researcher

Arkansas State University primary UA Little Rock NCTR University of Arkansas UAMS

Also affiliated: Ontario Institute for Cancer Research (2002); Arkansas Children's Hospital (2012–2019); San Francisco VA Medical Center (2020); United States Food and Drug Administration (2010); Emory University (2024); University of Alberta (2002–2003); Duke University (2020); Texas A&M University System (1998); University of California, San Francisco (2020); Middlesbrough College (1996–1997); Boston Scientific (United States) (2025); Thomas Jefferson National Accelerator Facility (2012); Helmholtz Munich (2020); Rosa (United States) (2020); Institute of Bioinformatics and Systems Biology (2020); Calcutta Research Group (1947); Halton General Hospital (1993); GGZ inGeest (2024); Arkansas Children's Nutrition Center (2016–2018); Loughborough Hospital (1996); Amsterdam University Medical Centers (2024); Arkansas Biosciences Institute (2020–2025); Indiana University – Purdue University Indianapolis (2020); University of Missouri–Kansas City (2024–2025); University of Pennsylvania (2020); University of California, Davis (2020); Vrije Universiteit Amsterdam (2024); Texas A&M University (1998); Icahn School of Medicine at Mount Sinai (2020)

Faculty Researcher

26 h-index 112 pubs 3,300 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Sudeepa Bhattacharyya's research focuses on the biological underpinnings of major depressive disorder, particularly through the lens of metabolomics and the gut microbiome. Her work investigates how metabolic alterations and microbial byproducts may contribute to the pathobiology of depression and anxiety. Bhattacharyya has published studies examining specific metabolite classes, such as acylcarnitines, amines, and lipids, and their associations with depression status, severity, and symptom profiles. Her research also explores the role of gut microbiome-derived compounds, like indoxyl sulfate and bile acids, in relation to mental health conditions.

Further research by Bhattacharyya has explored the relationship between medication use and distinct microbial features in anxiety and depression. She has also contributed to natural language processing in the medical field, developing concepts for colonoscopy compilation and annotating clinical discharge summaries for named entity recognition. Bhattacharyya's scholarly output is reflected in her h-index of 26 and over 3,258 citations from 112 publications. She has received federal funding for cyberinfrastructure modernization at Arkansas State University, serving as Co-PI on an NSF award of $99,906.

Metrics

h-index: 26
Publications: 112
Citations: 3,300

Selected Publications

Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2025)

Translational Psychiatry 13 citations DOI OpenAlex
Evaluating maternal drug use disparities, risk factors and outcomes in Northeast Arkansas: a pre, during, and post-COVID-19 pandemic analysis (2025)

BMC Public Health 2 citations DOI OpenAlex
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder (2025)

Journal of Affective Disorders 7 citations DOI OpenAlex
Medication use is associated with distinct microbial features in anxiety and depression (2025)

Molecular Psychiatry 17 citations DOI OpenAlex
Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2024)

Research Square DOI OpenAlex
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder (2024)

medRxiv 2 citations DOI OpenAlex
Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression (2024)

bioRxiv (Cold Spring Harbor Laboratory) 3 citations DOI OpenAlex
Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2024)

medRxiv DOI OpenAlex
Social Determinants of Health Data Quality at Different Levels of Geographic Detail (2023)

Studies in health technology and informatics 10 citations DOI OpenAlex
Social Determinants of Health Data Quality at Different Levels of Geographic Detail (2023)

medRxiv 3 citations DOI OpenAlex
Repeatable enhancement of healthcare data with social determinants of health (2022)

Frontiers in Big Data 3 citations DOI OpenAlex
Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety—A Role for Bile Acids (2022)

Frontiers in Neuroscience 72 citations DOI OpenAlex
Covid-19 Positivity Differences Among Patients of a Rural, Southern US State Hospital System Based on Population Density, Rural-Urban Classification, and Area Deprivation Index (2022)

Studies in health technology and informatics 4 citations DOI OpenAlex
Metabolomic and inflammatory signatures of symptom dimensions in major depression (2022)

Brain Behavior and Immunity 105 citations DOI OpenAlex
Automated Enhancement and Curation of Healthcare Data (2022)

medRxiv DOI OpenAlex